Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 285-290

  Gorse, Geoffrey J ^a   Otto, Esther E ^b   Powers, Douglas C ^b   Chambers, Guy W ^b   Eickhoff, Christopher S ^b   Newman, Frances K ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSTIMULATION; INFLUENZA VIRUS A; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; VIRUS ATTENUATION; VIRUS INACTIVATION;

EID: 0030061535     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.285     Document Type: Article

References (16)

1. Arden NH, Cox NJ, Schonberger LB. Prevention and control of influenza: part 1, vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1993;42(RR-6):1-14.
2. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987;82(suppl 6A):20-5.
3. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
4. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982;4:25-44.
5. Patriarca PA, Weber JA, Rarker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985;253:1136-9.
6. Monto AS. Influenza vaccines for the elderly [editorial]. N Engl J Med 1994;331:807-8.
7. Gorse GJ, Belshe RB, Munn NJ. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol 1988;26:911-8.
8. Gorse GJ, Belshe RB, Munn NJ. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 1991;100:977-84.
9. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/ 80 (H3N2) wild-type virus infection. Lancet 1984;1:705-8.
10. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986;23:66-72.
11. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986;154:121-7.
12. Zahradnik JM, Kasel JA, Martin RR, Six HR, Cate TR. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine. J Med Virol 1983;11:277-85.
13. Gorse GJ, Belshe RB. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand J Infect Dis 1991;23:7-17.
14. Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older chronically ill adults. J Clin Microbiol 1990;28:2539-50.
15. Gorse GJ, Campbell MJ, Otto EE, Powers DC, Chambers GW, Newman FK. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 1995;172:1-10.
16. Ennis FA, Yi-Hua Q, Schild GC. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J Gen Virol 1982;58:273-81.